233 related articles for article (PubMed ID: 29883317)
1. Kallikrein-related peptidases and associated microRNAs as promising prognostic biomarkers in gastrointestinal malignancies.
Adamopoulos PG; Tsiakanikas P; Scorilas A
Biol Chem; 2018 Jul; 399(8):821-836. PubMed ID: 29883317
[TBL] [Abstract][Full Text] [Related]
2. Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: mechanistic and clinical aspects.
Kontos CK; Mavridis K; Talieri M; Scorilas A
Thromb Haemost; 2013 Sep; 110(3):450-7. PubMed ID: 23446315
[TBL] [Abstract][Full Text] [Related]
3. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers.
Kontos CK; Scorilas A
Clin Chem Lab Med; 2012 Nov; 50(11):1877-91. PubMed ID: 23093268
[TBL] [Abstract][Full Text] [Related]
4. The miRNA-kallikrein interaction: a mosaic of epigenetic regulation in cancer.
Di Meo A; Wang C; Cheng Y; Diamandis EP; Yousef GM
Biol Chem; 2018 Sep; 399(9):973-982. PubMed ID: 29604203
[TBL] [Abstract][Full Text] [Related]
5. Kallikrein-related peptidases in cancers of gastrointestinal tract: an inside view of their role and clinical significance.
Linardoutsos D; Gazouli M; Machairas A; Bramis I; Zografos GC
J BUON; 2014; 19(1):53-9. PubMed ID: 24659643
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there.
Pasic MD; Olkhov E; Bapat B; Yousef GM
Biol Chem; 2012 Apr; 393(5):319-30. PubMed ID: 22505515
[TBL] [Abstract][Full Text] [Related]
7. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers.
Emami N; Diamandis EP
Clin Chem; 2008 Oct; 54(10):1600-7. PubMed ID: 18687738
[TBL] [Abstract][Full Text] [Related]
8. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
Avgeris M; Scorilas A
Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies.
Dorn J; Bayani J; Yousef GM; Yang F; Magdolen V; Kiechle M; Diamandis EP; Schmitt M
Thromb Haemost; 2013 Sep; 110(3):408-22. PubMed ID: 23765253
[TBL] [Abstract][Full Text] [Related]
10. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
Scorilas A; Mavridis K
Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
[TBL] [Abstract][Full Text] [Related]
11. Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
Figueroa CD; Molina L; Bhoola KD; Ehrenfeld P
Biol Chem; 2018 Sep; 399(9):937-957. PubMed ID: 29885274
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs.
White NM; Bui A; Mejia-Guerrero S; Chao J; Soosaipillai A; Youssef Y; Mankaruos M; Honey RJ; Stewart R; Pace KT; Sugar L; Diamandis EP; Doré J; Yousef GM
Biol Chem; 2010 Apr; 391(4):411-23. PubMed ID: 20180642
[TBL] [Abstract][Full Text] [Related]
13. The prognostic and diagnostic potential of kallikrein-related peptidases in ovarian cancer.
Riedel M; Bronger H; Magdolen V; Dreyer T
Expert Rev Mol Diagn; 2021 Jun; 21(6):535-545. PubMed ID: 33947310
[No Abstract] [Full Text] [Related]
14. The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.
Kryza T; Silva ML; Loessner D; Heuzé-Vourc'h N; Clements JA
Biochimie; 2016 Mar; 122():283-99. PubMed ID: 26343558
[TBL] [Abstract][Full Text] [Related]
15. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer.
Talieri M; Li L; Zheng Y; Alexopoulou DK; Soosaipillai A; Scorilas A; Xynopoulos D; Diamandis EP
Br J Cancer; 2009 May; 100(10):1659-65. PubMed ID: 19367279
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry based proteomics analyses in kallikrein-related peptidase research: implications for cancer research and therapy.
Silva LM; Clements JA
Expert Rev Proteomics; 2017 Dec; 14(12):1119-1130. PubMed ID: 29025353
[TBL] [Abstract][Full Text] [Related]
17. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance.
Avgeris M; Mavridis K; Scorilas A
Biol Chem; 2012 Apr; 393(5):301-17. PubMed ID: 22505514
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers.
Macha MA; Seshacharyulu P; Krishn SR; Pai P; Rachagani S; Jain M; Batra SK
Curr Pharm Des; 2014; 20(33):5287-97. PubMed ID: 24479799
[TBL] [Abstract][Full Text] [Related]
19. Kallikrein-related peptidases (KLKs) and the hallmarks of cancer.
Filippou PS; Karagiannis GS; Musrap N; Diamandis EP
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):277-91. PubMed ID: 26886390
[TBL] [Abstract][Full Text] [Related]
20. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer.
White NM; Youssef YM; Fendler A; Stephan C; Jung K; Yousef GM
Biol Chem; 2012 Apr; 393(5):379-89. PubMed ID: 22505520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
